retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide, a TRIPLE agonist (GLP1,

Intravenous vitamin therapy (IV) nutritional support (essential vitamins, minerals, amino acids, antioxidants) through an intravenous drip so they are absorbed directly into your bloodstream bypassing obstacles in your digestive system that may hinder absorption

J Environ Chem Eng 7:103169 Sayed AEDH, AbdAllah EA, Hamed M, Soliman HAM (2020) Hepato-nephrotoxicity in late juvenile of Oreochromis niloticus exposed to gibberellic acid: ameliorative effect of Spirulina platensis

The native GHRH structure contains regions with suboptimal -helix probability, particularly at positions 8, 9, and 15, where competing -turn formation reduces structural stability

34 (1), 5974.e10

Why Women in Menopause & Perimenopause Struggle With Weight Loss During perimenopause and menopause , estrogen and progesterone levels fluctuate, impacting metabolism, fat storage, and insulin response

Your BMI and Comorbidities Still Meet Surgical Criteria Adults qualify for bariatric surgery with a BMI of 35 or higher with at least one obesity-related health condition (such as type 2 diabetes, hypertension, or sleep apnea), or for those with a BMI of 40 or higher regardless of comorbidities